StockWatch
·

Cosmic CRF Ltd Q2 FY27 Results

COSMICCRFQ2 FY27 Results
Filing
COSMIC CRF · Q2 FY-2027 · THE VERDICT

Strong Order Book, Missing Profit: Cosmic CRF's Unverified 20% Growth Bet

Order book surged 48% to ₹612 Crore and the long-term capacity roadmap to 1.75 lakh MT is credible. But management disclosed zero P&L for H1 FY27 while maintaining 20-25% full-year growth guidance, leaving the biggest claim of the quarter unverified and earnings quality suspect.

12 Nov 2026 · 6 min read
Order book

₹612 Cr

+48% YoY from ₹414 Cr

FY27 growth guidance

+20-25%

revenue on top of FY26

H1 FY27 P&L

Not disclosed

only volumes (43.2k MT) reported

Portfolio utilization

78.6%

flat vs 80% prior year

On paper, Cosmic CRF had a strong quarter: order book grew 48%, the long-term capacity roadmap to 1.75 lakh MT by FY30 is grounded in concrete mechanics, and management walked through credible segment economics (springs 25% margins, forging 14-15% PAT). But the call also revealed a glaring void: the company maintained 20-25% full-year revenue growth guidance for FY27 without disclosing a single P&L figure for H1 FY27. Management provided volumes (Cosmic CRF 21,110 MT, NS Engineers 22,124 MT), order book, and forward guidance. No revenue. No profit. No year-over-year P&L comparison. This leaves the most important claim of the quarter — that the company has "grown in strength on top and bottom lines" — unverified and overstated.

The missing P&L

Listed just over three years ago (Jun 2023), Cosmic CRF has built a credible narrative: 1,000% capacity CAGR, order book diversification into infrastructure (78% of new orders), and margin expansion via springs and forging. On this call, management was transparent and specific. Springs economics: ₹18k COGS, ₹30k selling price, 25% margins on 5,000 MT capacity. Forging: ₹115-120 Crore turnover at 14-15% PAT. The data was granular and checkable. But when pressed on H1 FY27 actual results, the company provided only volumes — a stark omission for a publicly listed company in Q3 of its earnings cycle. This makes it impossible to reconcile whether the 78.6% utilization figure is being leveraged into margin expansion or being eroded by competitive price pressure. The claim of YoY "strength on top and bottom lines" cannot be independently verified.

H1 FY27 Capacity Utilization %
029.8759.7389.638Cosmic CRF standalone34NS Engineers standalone78.6Full portfolio blended80Prior year portfolio
Core wagon businesses (Cosmic CRF 38%, NS Eng 34%) are performing weakly. The portfolio-level 78.6% blends in higher-utilization springs and forging divisions. Flat YoY despite 48% order book growth signals either pricing pressure or weak conversion.
Management claims vs. what holds up

Order book grew 39-40% to ₹612 Cr

Evidence / Reality

₹414 Cr (prior year) to ₹612 Cr now = 47.8% growth confirmed independently

Verdict

Supported (48% growth)

Capacity utilization 78.6% across portfolio

Evidence / Reality

Cosmic CRF 21,110 MT / 55,000 = 38%; NS Eng 22,124 MT / 65,000 = 34%; blended reported 78.6% (incl. springs/forging)

Verdict

Supported but flat YoY

H1 FY26 to H1 FY27 we've grown in strength on top and bottom lines

Evidence / Reality

Only volumes disclosed (21,110 MT, 22,124 MT). No revenue, profit, or margin figures provided for H1 comparison.

Verdict

Overstated; unverified

Legal costs one-time impact in H1; H2 much lower

Evidence / Reality

Other expenses ₹6.5-7 Cr in H1 FY27 vs ₹6.5 Cr in prior H1; cost tied to NCLT Supreme Court case won in March. Normalization expected H2.

Verdict

Supported (₹0.5-1 Cr H1 impact estimated, H2 to normalize)

What changed on this call

Three material shifts in positioning. First, order book diversification: 78% of the ₹612 Cr order book now comes from infrastructure (railways, freight, civil projects) rather than pure wagon OEMs. Railway exposure reduced to 22%, de-risking customer concentration. This is genuine risk mitigation. Second, Amzen strategy firmed: Management walked through a credible playbook — ₹32 Crore upfront payment + ₹28 Crore security deposit post-NCLT approval, 6-month refurbishment cycle, April-May 2027 commercial production, 25% capacity unlock by FY28. The asset adds 1.5 lakh MT installed capacity and unlocks adjacent markets (wagon repair, loco shells, containers — upside ₹400+ Crore revenue at 25% utilization). Third, segment margins clarified: Springs (5,000 MT capacity) targeting ₹140-150 Crore revenue at 25% EBITDA; forging (11,000 MT) at ₹115-120 Crore turnover with 14-15% PAT; blended portfolio targeting 12-14% PAT by FY30. This specificity restored analyst confidence that the long-term narrative is grounded in real economics, not abstractions.

The bull-bear ledger

  • Structural wagon demand: India needs 60-70k wagons per year; current capacity ~36k wagons/year. 8-lakh wagon gap by 2031 (target) creates multi-decade growth runway.

  • Order book growth 48% YoY to ₹612 Cr is independently verifiable and provides 2-3 quarter revenue pipeline visibility.

  • Capacity roadmap to 1.75 lakh MT by FY30 is credible: Amzen +1.5 lakh MT, springs/forging expansions +35% from current level.

  • Springs 25% EBITDA margins and forging 14-15% PAT significantly exceed core wagon 10-12% margins; portfolio lift is material.

  • H1 FY27: zero P&L disclosed. Only volumes provided. Growth claim on 'top and bottom lines' cannot be independently verified.

  • Utilization flat at 78.6% YoY despite order book up 48%. Standalone Cosmic CRF only 38% utilized vs 55,000 MT capacity. Suggests weak price realization or execution.

  • Amzen approval still pending NCLT final order (Nov 25, 2026 hearing). Procedural delays endemic in Indian courts; worst case 6+ month slippage.

  • Macro headwinds: West Asia fiscal crisis and railway capex delays slowing order conversion. MD acknowledged 'first half always weak'; H2 recovery unproven.

  • Capex funding strain: ₹200+ Cr Amzen capex + existing debt obligations. Bankers stretched; fund houses holding 26% of NS subsidiary. Refinancing risk.

  • Concentrated ownership (55% promoter, 0.09% FII) and 57% drawdown from ATH. Institutional skepticism evident. Illiquid micro-cap stock with limited exit windows.

How the street is positioned

The market has rendered its verdict with brutal efficiency: no, not yet. At ₹935 (as of Nov 11, 2026), the stock sits 57.69% below its all-time high of ₹2,210 and trades below all three key moving averages (SMA200 ₹1,073, SMA50 ₹1,152, SMA20 ₹966). RSI 40.9 sits in neutral-to-oversold territory. This is not panic liquidation (volume trend is normal) but a methodical repricing as the story has matured from "early-stage capacity compounder" into "execution-dependent micro-cap with unproven margins and binary Amzen bet." The decline is rational: order book growth alone does not justify premium valuations if utilization stalls and P&L remains hidden.

Ownership patterns confirm the skepticism. Promoter holding has risen to 55.10% (Q4 FY26), signaling founders are accumulating on weakness. But FII ownership has collapsed to 0.09% — a stark reversal from 6.54% just two years ago (Q4 FY24). DII holding is steady but modest at 10.39%. This is not a portfolio that institutions are positioning for an Amzen ramp or a margin inflection. The vacuum of large institutional support in a ₹200+ Crore capex story and a 1.75 lakh MT capacity bet is a material red flag. It signals the street does not believe either the Amzen timeline or the margin story until it sees audited numbers.

The debate

Risks, ranked by how much they should concern a holder

Execution and regulatory risks that determine the outcome

H1 FY27 P&L not disclosed; earnings quality suspect

HIGH

Can't verify growth claim or margin trajectory. If Q4 FY27 results show flat or negative YoY profit, the 20-25% guidance narrative collapses and stock can re-rate to ₹550-650.

Amzen NCLT final order pending (Nov 25, 2026 hearing)

HIGH

Procedural delays endemic in Indian courts. If approval slips 6+ months (to Jan-Feb 2027), then 6-month refurbishment delays production to Aug-Sep 2027, pushing 25% FY28 capacity unlock into FY29. FY28 revenue guidance will miss by 20-25%.

Utilization flat at 78.6% YoY despite order book +48%

MEDIUM-HIGH

Divergence suggests pricing pressure or weak conversion. If H2 also shows flat utilization, it signals demand is not translating to revenue at guided ASP. May force margin guidance down.

Macro slowdown (West Asia fiscal crisis, railway delays)

MEDIUM-HIGH

Order book growth may not convert if government capex budgets freeze. MD already acknowledged 'first half always weak' and hedged H2. If Q3-Q4 also disappoint, FY27 20-25% growth guidance will be missed.

Capex funding strain (₹200+ Cr Amzen + debt burden)

MEDIUM

Bankers stretched; fund houses holding 26% NS subsidiary. If working capital cycles stretch or order delays hit, cash runway could tighten. Refinancing risk increases with lower equity valuations.

Concentrated ownership (55% promoter, 0.09% FII) and illiquidity

MEDIUM

Limited institutional support or buyback potential if underperformance occurs. Illiquidity could spike if bearish sentiment builds. Exit windows narrow for large holders.

What to watch next

Concrete milestones that will resolve the debate
  • 1 · NCLT Amzen final order (expected Nov 25, 2026)

    If approval comes in Nov, refurbishment begins immediately and April-May 2027 commercial production becomes credible. If approval delays to Dec 2026 or later, the 25% FY28 capacity unlock shifts to FY29. This is the binary gate.

  • 2 · H1 FY27 P&L disclosure (in Q4 results, Jan-Feb 2027)

    When Q4 FY27 results arrive, they will include H1 FY27 revenue/PAT. If YoY growth is 20-25%+, guidance is vindicated and stock can re-rate 30-40%. If growth is <10% or flat, the flat 78.6% utilization confirms pricing pressure and stock could re-test ₹650.

  • 3 · Forging commercial production start (target Dec 2026)

    Civil work commencing, transformers & CNC to arrive by Dec, then ramp. If Dec timeline holds, it signals execution credibility across the portfolio. If slip, raises questions about project management on Amzen.

  • 4 · Springs field trial RDSO approval (6-month cycle completion ~Nov-Dec 2026)

    Springs division running 3,000-set field trials (6 months from call). If trials pass without new fatigue tests, 25% springs margins become de-risked and portfolio PAT guidance has a credible floor.

Cosmic CRF's long-term story is compelling: structural wagon demand, credible 1.75 lakh MT roadmap, attractive springs/forging margins. But the quarter itself is frustrating. Management provided zero P&L for H1 FY27 while maintaining 20-25% full-year growth guidance. Utilization flatlined at 78.6% despite order book up 48%. Amzen — the catalyst — remains a Nov 25 court decision away. The market's 57% repricing from ₹2,210 to ₹935 is rational: this is no longer a 'growth compounder' trade; it's a 'prove-it' trade.

Holders should wait for Nov 25 (Amzen NCLT order) and Q4 FY27 results (~Jan-Feb 2027, which will include H1 FY27 P&L). Fresh buyers should stage in after Amzen closure OR after H1 P&L shows verified 20%+ growth, not before. The risk/reward is balanced only at ₹550-650 (IPO band); current levels price in near-term uncertainty and rightfully so.

The number to track: H1 FY27 reported revenue and PAT (disclosed in Q4 results, Jan-Feb 2027). If YoY growth <15%, thesis is broken and stock likely tests ₹550-650. If growth is 20%+, and NCLT approves Amzen by Dec 2026, the stock can re-rate to ₹1,200-1,400 by end-FY27. Until then, Hold.

Informational and educational content only. Not investment advice.